David Linetsky Sells 6,038 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 6,038 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $98,781.68. Following the completion of the transaction, the insider owned 223,942 shares in the company, valued at approximately $3,663,691.12. This represents a 2.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

David Linetsky also recently made the following trade(s):

• On Thursday, January 15th, David Linetsky sold 1,743 shares of Phreesia stock. The shares were sold at an average price of $16.38, for a total transaction of $28,550.34.
• On Thursday, January 8th, David Linetsky sold 6,106 shares of Phreesia stock. The shares were sold at an average price of $17.01, for a total value of $103,863.06.
• On Wednesday, December 17th, David Linetsky sold 94 shares of Phreesia stock. The stock was sold at an average price of $16.49, for a total value of $1,550.06.

Phreesia Trading Down 0.9%

Shares of NYSE PHR opened at $15.59 on Thursday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $939.62 million, a PE ratio of -155.83 and a beta of 0.61. Phreesia, Inc. has a twelve month low of $15.40 and a twelve month high of $32.76. The stock has a fifty day simple moving average of $17.94 and a 200-day simple moving average of $23.03.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. During the same quarter in the prior year, the company earned ($0.25) EPS. Phreesia’s revenue was up 12.7% on a year-over-year basis. On average, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several large investors have recently bought and sold shares of PHR. Loomis Sayles & Co. L P purchased a new position in Phreesia in the second quarter valued at approximately $34,162,000. Millennium Management LLC lifted its position in shares of Phreesia by 730.7% during the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after buying an additional 936,033 shares during the last quarter. Greenhouse Funds LLLP boosted its holdings in shares of Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Phreesia by 1,065.9% in the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock valued at $13,043,000 after buying an additional 506,954 shares during the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in Phreesia during the 3rd quarter worth $11,395,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Recent operating results show improvement: Phreesia beat consensus EPS and reported revenue growth (quarterly revenue up ~12.7% year‑over‑year), supporting the business case for recovery at current multiples. MarketBeat PHR profile
• Positive Sentiment: Wall Street remains largely constructive — most analysts rate PHR a Buy and the consensus price target (~$30) is well above the current trading level, giving upside if growth continues. Analyst consensus
• Neutral Sentiment: Although insiders sold sizable blocks, each still retains a material stake after the trades (examples from filings: Evan Roberts ~826k, David Linetsky ~224k, Allison Hoffman ~170k, Balaji Gandhi ~150k, Amy Vanduyn ~159k), which may temper concerns about a loss of long‑term conviction. InsiderTrades summary
• Neutral Sentiment: Market context: volume is slightly above average and the stock is trading below its 50‑ and 200‑day moving averages and near its 52‑week low — conditions that can amplify moves but also offer a potential entry if fundamentals improve. Price performance
• Negative Sentiment: Coordinated insider selling is the primary near‑term driver of weakness: multiple senior executives sold on Jan 15–16 at ~ $16.36–$16.38 (combined ~29,511 shares). Visible, same‑period sales by several officers can prompt short‑term selling pressure as other holders react. Evan Roberts sale (example)
• Negative Sentiment: Insider sales may be interpreted as liquidity or diversification events rather than vote of no confidence, but absent clarifying disclosure (e.g., 10b5‑1 plans, option exercises) the market tends to treat clustered insider sales as a negative signal. SEC filings

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PHR shares. Citigroup cut their target price on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, January 9th. Truist Financial set a $24.00 price objective on Phreesia in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a report on Friday, October 31st. Canaccord Genuity Group lowered their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, December 9th. Finally, Barclays cut their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Seventeen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.